Sarepta CFO shares withheld for RSU tax

Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported routine share dispositions tied to tax withholding on restricted stock unit vesting.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported routine share dispositions tied to tax withholding on restricted stock unit vesting. On March 9, 2026, a total of 275 shares of common stock were withheld by the company to cover tax obligations from RSUs granted in 2022 and 2023. Following these tax-withholding events, Wong directly holds 135,320 shares of Sarepta common stock, so the withheld amount represents a modest adjustment to his overall equity position rather than an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 275 shares

Exercise Price or Tax Liability 2 txns

Insider Wong Ryan Ho-Yan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	162	$16.95	$3K
Exercise Price or Tax Liability	Common Stock	113	$16.95	$2K

Holdings After Transaction: Common Stock — 135,320 shares (Direct)

Footnotes (2)

1. F1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.
2. F2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta Therapeutics (SRPT) report for its CFO?

Sarepta Therapeutics reported that CFO Ryan Ho-Yan Wong had 275 shares of common stock withheld to satisfy tax obligations on vested restricted stock units. These transactions are coded as tax-withholding dispositions and do not represent open-market buying or selling of shares.

How many Sarepta (SRPT) shares were withheld for the CFO’s tax obligations?

A total of 275 Sarepta common shares were withheld to cover CFO Ryan Ho-Yan Wong’s tax obligations related to restricted stock unit vesting. The amounts were 162 shares from a 2022 grant and 113 shares from a 2023 grant, all withheld by the company.

Does the Sarepta (SRPT) CFO still hold a significant share position after this Form 4?

Yes. After the tax-withholding dispositions, CFO Ryan Ho-Yan Wong directly holds 135,320 Sarepta common shares. The 275 withheld shares are small compared with his remaining position, indicating this was a routine tax event rather than a large change in ownership.

Were the Sarepta (SRPT) CFO’s transactions open-market sales or tax withholdings?

The transactions were tax withholdings, not open-market sales. Shares were withheld by Sarepta to satisfy tax obligations upon vesting of restricted stock units granted in March 2022 and March 2023. The Form 4 uses transaction code F for these dispositions.

What do the Sarepta (SRPT) footnotes say about the CFO’s Form 4 transactions?

The footnotes explain that the withheld shares satisfied tax withholding obligations from vesting of restricted stock units granted on March 7, 2022, and March 6, 2023. This clarifies that the dispositions are mechanical tax events administered by the company, not discretionary market trades.

Are there any remaining derivative or option positions disclosed for the Sarepta (SRPT) CFO?

The filing’s derivative section is empty, indicating no derivative transactions were reported in this Form 4. The reported activity is limited to non-derivative common stock withheld for taxes on RSU vesting, with no option exercises or other derivative events disclosed here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 08:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wong Ryan Ho-Yan

(Last) (First) (Middle)

215 FIRST STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		F(1)		162	D	$16.95	135,433	D
Common Stock	03/09/2026		F(2)		113	D	$16.95	135,320	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ryan Ho-Yan Wong	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.